2m 2m 2m 2m 2m 2m 2m
Cullinan Thera (CGEM)
NASDAQ
$17.34-$0.41 (-2.30%)
Price as of Jun 23, 2026 7:50 PM EDT- $1.1BMarket Cap
- 126.40%1-Year Change
- BiotechnologyIndustry
Cullinan Thera (CGEM)
$17.34-$0.41 (-2.30%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | 0 -100.00% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 -100.00% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -187.4M +31.14% | -142.9M -3.55% | -148.2M +61.13% | -91.9M +59.21% | |
Depreciation and Amortization Expense | 311,000 +1.63% | 306,000 -1.29% | 310,000 +233.33% | 93,000 +75.47% | |
Total Operating Expenses | 241.6M +22.71% | 196.9M +3.29% | 190.6M +44.28% | 132.1M +52.06% | |
Operating Profit | -241.6M +22.71% | -196.9M +3.05% | -191.1M -232.11% | 144.6M +312.86% | |
Interest Income | 22.2M -25.11% | 29.7M +37.14% | 21.6M +227.14% | 6.6M +1,285.95% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 22.2M -25.11% | 29.7M +37.14% | 21.6M +227.14% | 6.6M +1,285.95% | |
Total Nonoperating Income and Expense | -443,000 +122.61% | -199,000 -183.26% | 239,000 +319.30% | 57,000 +812.50% | |
Income before Taxes | -219.9M +31.30% | -167.5M -1.04% | -169.2M -211.83% | 151.3M +322.67% | |
Income Taxes | 0 -100.00% | 117,000 +100.83% | -14.1M -133.53% | 42.1M N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -219.9M +31.36% | -167.4M +9.28% | -153.2M -237.72% | 111.2M +269.61% | |
Net Income from Continuing Operations Applicable to Common | -219.9M +31.30% | -167.5M -1.04% | -169.2M -211.83% | 151.3M +330.77% | |
Basic EPS and Net Income | -3.36 +20.86% | -2.78 -24.66% | -3.69 -250.00% | 2.46 +261.84% | |
Diluted EPS and Net Income | -3.36 +20.86% | -2.78 -24.66% | -3.69 -255.04% | 2.38 +256.58% | |
Basic Weighted Average Shares | 59.0M +9.82% | 53.8M +29.41% | 41.5M -8.00% | 45.2M +4.84% | |
Diluted Weighted Average Shares | 59.0M +9.82% | 53.8M +29.41% | 41.5M -10.91% | 46.6M +8.27% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 88.3M +6.42% | 83.0M -15.67% | 98.4M -36.96% | 156.2M +161.24% | |
Short-Term Investments | 289.6M -8.36% | 316.0M -14.29% | 368.6M +18.48% | 311.1M +34.87% | |
Cash and Cash Equivalents and Short-Term Investments | 377.9M -5.28% | 399.0M -14.58% | 467.1M -0.05% | 467.3M +60.88% | |
Total Current Assets | 386.8M -6.73% | 414.7M -13.65% | 480.2M +1.21% | 474.5M +59.99% | |
Accumulated Depreciation | 969,000 +47.26% | 658,000 +86.93% | 352,000 +160.74% | 135,000 -41.81% | |
Property and Plant and Equipment and Net | 421,000 -38.36% | 683,000 -30.94% | 989,000 -15.76% | 1.2M +1,424.68% | |
Total Long-Term Assets | 297,000 -18.85% | 366,000 -20.26% | 459,000 0.00% | 459,000 +212.24% | |
Total Assets | 448.4M -27.89% | 621.8M +28.43% | 484.2M -13.71% | 561.1M +28.35% | |
Income Taxes Payable | 0 N/A | 0 N/A | 0 -100.00% | 4.3M N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 37.7M +23.15% | 30.6M +8.92% | 28.1M +25.06% | 22.5M +91.54% | |
Total Long-Term Debt | N/A N/A | 0 -100.00% | 2.0M N/A | N/A N/A | |
Total Long-Term Liabilities | 1.9M +124.15% | 849,000 -60.51% | 2.1M -40.11% | 3.6M +5,423.08% | |
Total Liabilities | 39.6M +25.87% | 31.5M +3.99% | 30.3M +16.10% | 26.1M +120.88% | |
Retained Earnings | -588.1M +59.71% | -368.2M +83.33% | -200.9M +321.13% | -47.7M -69.99% | |
Total Stockholders Equity | 408.7M -30.76% | 590.3M +30.11% | 453.7M -15.20% | 535.0M +25.90% | |
Total Shares Outstanding | 60.2M +2.96% | 58.5M +36.39% | 42.9M -6.32% | 45.8M +3.40% | |
Cash Flow | |||||
Cash from Operating Activities | -175.8M +20.95% | -145.3M +8.21% | -134.3M +6.01% | -126.7M +191.63% | |
Capital Expenditures | 49,000 N/A | 0 -100.00% | 208,000 -81.64% | 1.1M +11,230.00% | |
Cash from Investing Activities | 180.0M +232.04% | -136.3M -480.70% | 35.8M -85.62% | 249.0M +174.59% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 1.1M -99.59% | 266.2M +553.21% | 40.8M +257.14% | -25.9M -109.65% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -41.09% +35.76% | -30.27% +3.29% | -29.30% -231.53% | 22.28% N/A | |
Return on Equity | -44.02% +37.28% | -32.06% +3.50% | -30.98% -233.72% | 23.17% N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | -100.00% N/A | |
Current Ratio | 10.25 -24.26% | 13.53 -20.72% | 17.07 -19.08% | 21.09 N/A | |
Cash Ratio | 2.34 -13.58% | 2.71 -22.58% | 3.50 -49.60% | 6.94 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow